OpenPV Signal Explorer
FAERS disproportionality dashboard
Reaction

Carcinoembryonic Antigen Increased reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,906 reports · 52 co-occurring drugs

As of the last recalculation, Carcinoembryonic Antigen Increased appears in 1,906 FAERS reports alongside 52 co-occurring drug terms. The strongest observed disproportionality signal is REGORAFENIB (PRR 100.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Regorafenib101100.3101.1
Panitumumab9368.168.5
Ribociclib15156.756.9
Trifluridine And Tipiracil5052.252.5
Fulvestrant13447.647.8
Alpelisib3139.539.6
Gefitinib3239.439.5
Letrozole17133.233.3
Osimertinib9032.132.2
Letrozole Tablets13031.631.7
Capecitabine19926.426.5
Ado-Trastuzumab Emtansine2026.226.2
Crizotinib2925.325.3
Oxaliplatin14923.723.8
Irinotecan Hydrochloride2622.422.4
Cetuximab5118.218.3
Exemestane3518.218.2
Fluorouracil Cream, 0.5%11717.817.8
Fluorouracil11717.517.6
Encorafenib1516.716.7
Leucovorin Calcium2615.015.1
Bevacizumab15614.914.9
Zoledronic Acid4512.512.5
Goserelin1512.312.3
Pemetrexed Disodium3710.810.8
Trastuzumab6510.710.7
Anastrozole3510.610.6
Erlotinib Hydrochloride1210.510.5
Palbociclib8710.410.4
Durvalumab1910.310.3
Erlotinib910.210.2
Everolimus459.99.9
Pemetrexed199.89.8
Anastrozole Tablets199.89.8
Telmisartan159.29.2
Everolimus Tablets149.29.2
Lapatinib128.58.5
Prochlorperazine Maleate78.38.3
Abemaciclib158.38.3
Fam-Trastuzumab Deruxtecan-Nxki66.56.5
Niraparib136.46.4
Pembrolizumab566.06.0
Pertuzumab145.75.7
Paclitaxel475.35.3
Paclitaxel (Aibumin-Bound)385.15.1
Denosumab905.05.0
Cisplatin334.74.7
Olaparib84.24.2
Gemcitabine Hydrochloride193.93.9
Atezolizumab133.73.7
Romosozumab-Aqqg32.42.4
Relugolix41.91.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.